细胞色素 P450 氧化酶 CYP2D6 基因缺失被推测是药物诱导肝脏中毒和心脏衰竭的危险因素,但是尚未确定两者之间明确的临床关联。[9]Carvalho M, Carmo H, Costa VM, et al. Toxicity of amphetamines: an update. Arch Toxicol. 2012;86:1167-1231.http://www.ncbi.nlm.nih.gov/pubmed/22392347?tool=bestpractice.com[32]Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994;47:1151-1156.http://www.ncbi.nlm.nih.gov/pubmed/7909223?tool=bestpractice.com[33]Maurer HH, Kraemer T, Springer D, et al. Chemistry pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther Drug Monit. 2004;26:127-131.http://www.ncbi.nlm.nih.gov/pubmed/15228152?tool=bestpractice.com[34]Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit. 2002;24:277-289.http://www.ncbi.nlm.nih.gov/pubmed/11897973?tool=bestpractice.com[35]Sutter ME, Gaedigk A, Albertson TE, et al. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clin Toxicol (Phila). 2013;51:540-544.http://www.ncbi.nlm.nih.gov/pubmed/23855716?tool=bestpractice.com